metabolism |
CYP2D6, CYP1A2 (minor) |
96 |
psychiatric dose |
4 to 32 mg/d |
96 |
metabolites
|
Perphenazine sulfoxide,
Dealkyl perphenazine
|
96
|
half-life |
~ 10 hours, blood |
96, 97 |
common blood level
|
1 to 10 nmol/L
1.5 ng/ml perphenazine = 3.7 nmol/L
0.8 ng/ml perphenazine sulfoxide,
2.0 ng/ml dealkyl perphenazine
|
98, 99, 103
|
Side effects >5% |
day sedation at > 8 mg/day |
102 |
Side effects 1-5% |
akathisia, hyperprolactinemia, hypotension, sexual
dysfunction, mainly at >8 mg/d |
102 |
Side effects <1% |
neuroleptic malignant syndrome |
89 |
psychiatric use |
antipsychotic, antidepressant augmentation, agitation
states |
102 |
other uses |
anti-nausea, antipruritic, anti-vertigo |
84,100,
101 |